<DOC>
	<DOCNO>NCT01219764</DOCNO>
	<brief_summary>The propose study test hypothesis H. pylorus eradicate successfully ( &gt; 85 % ) use half-or full-dose `` concomitant '' non-bismuth quadruple therapy regimen : rabeprazole , amoxicillin , clarithromycin metronidazole twice daily 7 day patient peptic ulcer H. pylori relate gastritis . Two hundred patient outpatient department endoscopy unit AUBMC enrol open-label trial . Patients positive CLO test urea breath test , document H.pylori infection , randomize one two group : Full dose half dose concomitant regimen , 100 patient group . Compliance side effect assess , urea breath test do patient 4 week therapy completion evaluate eradication rate . Success therapy evaluate accord intent-to treat per-protocol analysis .</brief_summary>
	<brief_title>A Trial Standard v Half Dose Rabeprazole , Clarithromycin , Metronidazole Amoxicillin Treatment Helicobacter Pylori Infection</brief_title>
	<detailed_description>Infection H. pylorus link chronic active gastritis , peptic ulcer disease , adenocarcinoma Non-Hodgkin 's lymphoma stomach . Eradication organism recommend patient peptic ulcer disease , low-grade gastric mucosa-associated lymphoid tissue lymphoma , atrophic gastritis , unexplained iron deficiency anemia , chronic idiopathic thrombocytopenic purpura , well first-degree relative gastric cancer patient . Guidelines still recommend use triple therapy regimen PPI , clarithromycin amoxicillin/metronidazole twice daily 7 14 day . Over year , become clear first-line triple therapy loose efficacy worldwide PP ITT eradication rate inferior 80 % . Antimicrobial resistance play important role failure . Major H. pylorus study group world agree alternative treatment regimen urgently need . So far , 2 alternative treatment regimen show superiority first-line treatment protocol : sequential therapy consist combination amoxicillin PPI twice day 5 day follow another 5 day PPI plus clarithromycin tinidazole/metronidazole , concomitant non-bismuth quadruple regimen consist PPI , clarithromycin , metronidazole , amoxicillin twice daily . The propose study test hypothesis H. pylorus eradicate successfully ( &gt; 85 % ) use half-or full-dose `` concomitant '' non-bismuth quadruple therapy regimen : rabeprazole , amoxicillin , clarithromycin metronidazole twice daily 7 day patient peptic ulcer H. pylori relate gastritis . Two hundred patient outpatient department endoscopy unit AUBMC enrol open-label trial . Patients positive CLO test urea breath test , document H.pylori infection , randomize one two group : Full dose half dose concomitant regimen , 100 patient group . Compliance side effect assess , urea breath test do patient 4 week therapy completion evaluate eradication rate . Success therapy evaluate accord intent-to treat per-protocol analysis .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>document H.pylori infection CLO test Urea Breath Test sign inform consent Age 18 old 80 year Allergies drug use Recent antibiotic therapy ( within 2 week enrolment ) Severe ulcer bleed Gastric perforation obstruction Previous gastrectomy Gastric cancer Pregnancy lactation Prior eradication therapy H. pylorus Severe concomitant disease condition make treatment unlikely effective i.e . alcoholism , drug addiction , history poor compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Helicobacter pylorus infection</keyword>
	<keyword>quadruple therapy</keyword>
	<keyword>Amoxicillin</keyword>
	<keyword>Metronidazole</keyword>
	<keyword>Clarithromycin</keyword>
	<keyword>Rabeprazole</keyword>
</DOC>